DTIL
Precision Biosciences Inc
$8.24
+0.06 (+0.73%)
At close · Jul 6
Market Cap
$212.61M
Shares
25,802,247
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.24
Open$7.95
Day$7.95–8.53
52W$3.53–8.82
Avg vol 30d488K
Short int1.9M · 7.5% float · 5.4d
Short vol42%
Last earningsMay 5, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 5
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Strong Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+43% above
+
Price vs 50-day avg
+15% above
◦
RSI (14)
68 · neutral
+
MACD trend
positive
+
52-week position
89% · near high
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $7 › 200d $6 — 50d above 200d
+
Institutional flow
+13% holders QoQ · +21 funds added
◦
Insider flow
No net insider activity over 90 days
−
Short interest
7.53% of float · ▲ +16.1% MoM · 5.4 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
78 holders — near 2-yr high, broad support
Fundamentals
Fair
−
EPS growth
−442% Y/Y
+
Balance sheet
net cash $88.6M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 1, 2026
Est · unconfirmed
· in 4 wks
FQ1-27 quarter ends
~Aug 21, 2026
Est
filed May 5, 2026
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+43% above
Bullish
Price vs 50-day avg
+15% above
Bullish
RSI (14)
68 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
89% · near high
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +21 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.53% of float · ▲ +16.1% MoM · 5.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
78 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $4
Now $8 · 89%
52-wk high $9
vs 200-day avg +43%
vs 50-day avg +15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DTIL
this stock
Precision Biosciences Inc
|
$212.61M | +98.1% | -50.1% | — | 7.5% |
|
AKTX
Akari Therapeutics Plc
|
$998.08B | -5.7% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$488.96B | +1.9% | +22179.2% | 995.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.92B | +16.8% | +46.2% | 31.1 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.33B | -15.7% | +20.8% | 16.1 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DTIL | +13.0% | +28.6% | +110.2% | +4.8% | +98.1% |
| SPY | +3.1% | -0.8% | +8.2% | +0.6% | +10.2% |
| vs SPY | +10.0% | +29.3% | +102.0% | +4.2% | +87.9% |